The rheumatoid arthritis (RA) market is set to experience increasing attrition due to biosimilar competition. The EU market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance of biosimilars compared to other countries. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence builds, with long-term data supporting biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars, encouraging uptake. 

As multibillion-dollar products, Humira and Enbrel represent the best-selling brands in the market, and their stronghold will continue. In the US, despite the 2023 entrance of eight adalimumab biosimilars with discounts ranging from 5% to 85%, with etanercept biosimilars held in patent litigation, substantial originator rebates, and exclusive contracting with payers, biosimilars are unlikely to completely supplant these two leading branded anti-TNFs. 

This Datamonitor Healthcare report contains a Disease Analysis module.